

Keratinocyte Carcinoma

A Review

Mackenzie R. Wehner, MD, MPhil

IMPORTANCE Keratinocyte carcinomas are skin cancers that arise from keratinocytes and are composed of basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs). Keratinocyte carcinomas are common in North America, Australia, New Zealand, and Europe. Approximately 5.4 million keratinocyte carcinomas are diagnosed in the US annually.

OBSERVATIONS Keratinocyte carcinomas are primarily located on the head and neck (40%-64% of BCCs; 35%-45% of cSCCs). BCC typically presents as a pink, smooth, raised lesion or a pink to red, flat lesion. cSCC typically presents as a red, scaly, flat lesion (in situ tumors) or a red, firm, raised lesion with scale or erosion (invasive tumors). UV light exposure is the primary cause, and lighter skin pigmentation and skin phototype (eg, skin that more easily burns) are the primary risk factors. Other risk factors include older age, male sex, indoor tanning, history of precancerous lesions (actinic keratoses), history of keratinocyte carcinomas, and immunosuppression (eg, organ transplant). In-office surgical excision or curettage and electrodesiccation (in which the tumor is scraped away using a curette and the wound base is cauterized) is typically performed by a dermatologist for keratinocyte carcinomas with lower risk of recurrence, including those that are nonrecurrent and have well-defined borders, small size, and location on the trunk and extremities. After surgical excision, approximately 3% of BCCs and 5% of cSCCs recur; after curettage and electrodesiccation, approximately 6% of BCCs and 2% of cSCCs recur. For keratinocyte carcinomas at higher risk of recurrence, in-office Mohs surgery (a technique in which a dermatologist with specialized training removes the tumor in stages and evaluates the entire surgical margin pathologically using a microscope after each stage to ensure complete tumor excision) is typically used. After Mohs surgery, approximately 4% of BCCs and 3% of cSCCs recur. Patients diagnosed with keratinocyte carcinoma are at high risk of additional keratinocyte carcinomas (approximately 40% within 5 years). Evidence-based prevention of keratinocyte carcinoma involves use of sunscreen. In a randomized clinical trial, use of daily sunscreen decreased cSCC risk (rate ratio, 0.62; 95% CI, 0.38-0.99; 1587 cSCCs per 100 000 person-years in controls vs 953 per 100 000 person-years in sunscreen group).

CONCLUSIONS AND RELEVANCE Keratinocyte carcinoma, composed of BCC and cSCC, is the most common cancer in the US, with an estimated 5.4 million diagnoses annually. Most keratinocyte carcinomas are effectively treated with in-office surgical procedures. Patients with keratinocyte carcinoma are recommended to undergo a skin examination at least annually due to their high risk of developing additional skin cancers.

JAMA. 2026;335(1):70-81. doi:10.1001/jama.2025.18749
Published online October 30, 2025.

 Multimedia

 CME at jamacmelookup.com

Author Affiliation: Department of Health Services Research and Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston.

Corresponding Author: Mackenzie R. Wehner, MD, MPhil, Department of Health Services Research, Department of Dermatology, University of Texas MD Anderson Cancer Center, 6900 Fannin St, FHB9.1098, Unit 733, Houston, TX 77030 (mwehner@mdanderson.org).

jama.com

Keratinocyte carcinomas, composed of basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (cSCCs), are the most common type of cancer in the US. The latest estimate using 2012 data indicated that there were approximately 5.4 million keratinocyte carcinomas in the US yearly,¹ more than all other cancers combined,² although the exact US incidence is uncertain due to absence of keratinocyte carcinoma registry data. Keratinocyte carcinoma primarily affects individuals with lighter skin pigmentation, and rates are highest in North America, Australia, New Zealand, and Western Europe.^{1,3-5} Keratinocyte carcinomas most commonly occur on the head and neck (approximately 50%),⁶ followed by the trunk for BCCs (15%-35%)⁶⁻⁹ and upper extremities for cSCCs (25%-35%).^{6,8,9} Typical treatments are in-office surgical procedures. For higher-risk keratinocyte carcinomas, Mohs surgery confers a 3% to 4% recurrence rate; for lower-risk keratinocyte carcinomas, standard excision has a 3% to 5% recurrence rate and curettage and electrodesiccation yields a 2% to 6% recurrence rate (over follow-up periods ranging from 3 months to 10 years).¹⁰⁻¹³ The risk of metastasis is low (0.004% of BCCs and 1.2%-1.9% of cSCCs),¹⁴⁻¹⁸ as is risk of mortality (0.08 per 100 000 person-years for BCC¹⁹ and 0.7-3.2 per 100 000 person-years for cSCC^{15,20,21}). This Review summarizes epidemiology and risk factors, clinical presentations, pathogenesis, assessment and diagnosis, treatment and prognosis, screening and surveillance, and prevention of keratinocyte carcinomas. The **Box** provides some common questions and answers about keratinocyte carcinomas. This Review does not include mucosal-adjacent cSCCs (eg, anogenital or lip cSCCs) and does not evaluate the role of teledermatology for diagnosing skin cancer.

Methods

An Ovid MEDLINE search was performed for English-language articles describing randomized clinical trials (RCTs), meta-analyses, systematic reviews, and cohort studies with keratinocyte carcinoma, BCC, or cSCC terms published between January 1, 2013, and July 31, 2025. Relevant studies of the epidemiology, risk factors, clinical presentation, pathogenesis, assessment, diagnosis, treatment, prognosis, screening, surveillance, or prevention of keratinocyte carcinomas were selected based on quality (rigor of study design, sample size, and follow-up). A total of 5871 publications were identified. This Review includes 99 articles (including 22 articles published prior to 2013 identified through reference lists of identified studies): 10 RCTs, 15 systematic reviews or meta-analyses, 7 guideline recommendations, 56 cohort or observational studies, 3 clinical references, 3 online data resources, 2 national/international agency reports, 2 public-facing American Academy of Dermatology websites, and 1 basic/translational science publication. For meta-analyses included in this Review, data are reported on absolute risk differences only when they were provided in the original report. For studies in which data were not reported separately for BCC and cSCC or the outcomes were similar, combined keratinocyte carcinoma outcomes are reported.

Pathogenesis

Keratinocyte carcinomas develop from epidermal keratinocytes. The primary cause of keratinocyte carcinoma is UV radiation. UV radia-

Box. Commonly Asked Questions About Keratinocyte Carcinomas

What Are the Risk Factors for Keratinocyte Carcinoma?

Common risk factors for keratinocyte carcinoma are exposure to UV radiation (natural sunlight and indoor tanning), lighter pigmentation and skin that more easily burns, red hair, older age, male sex, history of precancerous lesions (actinic keratoses), history of keratinocyte carcinoma, and immunosuppression (eg, organ transplant).

Where Do Keratinocyte Carcinomas Occur Most Commonly?

Approximately half of keratinocyte carcinomas occur on the head and neck. The next most common site is the trunk for basal cell carcinomas and the upper extremities for cutaneous squamous cell carcinomas.

How Often Should Patients With Keratinocyte Carcinomas Undergo Surveillance Skin Examinations?

Patients with keratinocyte carcinomas are at high risk of developing new keratinocyte carcinomas (approximately 40% within 5 years) and are also at increased risk of melanoma, so they are recommended to receive a full-body skin examination at least annually.

tion causes DNA damage as evidenced by characteristic mutation signatures, such as single base substitution of thymine for cytosine or tandem substitutions, in which an adjacent cytosine pair is exchanged for a thymine pair (UV mutation signatures present in 76% of BCCs²² and >50% of cSCCs²³). UV radiation also causes suppression of cell-mediated immune responses that inhibit the identification and destruction of tumor cells as well as tumor promotion that allows growth of damaged cells. The US Department of Health and Human Services and the International Agency for Research on Cancer both classify UV radiation as carcinogenic.^{24,25}

Epidemiology and Risk Factors

Epidemiology

Keratinocyte carcinomas are estimated to be among the most common cancers in North America, Australia, New Zealand, and Western Europe but are not included in most national cancer registries, including in the US. Epidemiologic estimates in the US are based on insurance claims for surgical treatment of keratinocyte carcinoma, which do not always distinguish between BCC and cSCC. The most recent comprehensive US estimate, from 2012 data, is that there were 5 434 193 treated keratinocyte carcinomas, which occurred in 3 315 554 patients.¹ In a cohort of US Medicare patients aged 65 years or older in 2009-2018 (4 999 999 persons), the annual incidence was 2.5% in American Indian or Alaska Native, 0.9% in Asian or Pacific Islander, 0.2% in Black or African American, 2.0% in Hispanic, and 11.5% in non-Hispanic White individuals.²⁶ The Netherlands Cancer Registry, which records keratinocyte carcinoma diagnoses, reported incidence rates of BCC at 292.71 per 100 000 person-years and of cSCC at 86.04 per 100 000 person-years in 2023.²⁷ BCCs are more common than cSCCs overall, but the ratio of BCCs to cSCCs (including cSCC in situ) is lower among older patients. A commercial US claims-based cohort (468 114 patients; 2012-2016) reported a BCC:cSCC ratio of 9.6:1 in 18- to 39-year-old individuals and 2.9:1 in 40- to 64-year-old individuals.²⁸ In the Netherlands Cancer Registry (2023), the BCC:

cSCC ratio ranged from 29.8:1 in individuals aged 30 to 44 years to 2:1 in those aged 75 years or older.²⁷ Mortality from BCC is rare (reported at 0.08 per 100 000 person-years).¹⁹ The Global Burden of Disease 2021 reports a global cSCC mortality rate of 0.72 per 100 000 person-years, with mortality rates per 100 000 person-years of 3.19 in Australia and New Zealand, 1.69 in Western Europe, and 1.53 in the US, Canada, and Greenland.²¹

Risk Factors

The primary risk factors for keratinocyte carcinoma are pigmentation characteristics and skin phototype (eg, skin response to sun exposure, sometimes described using the Fitzpatrick scale).²⁹ Having lighter skin pigmentation is associated with higher rates of BCC compared with darker skin pigmentation (odds ratio [OR], 2.11; 95% CI, 1.56-2.86) (meta-analysis of 12 cohort and case-control studies).³⁰ Having red hair is associated with BCC (OR, 2.02; 95% CI, 1.68-2.44 vs dark-colored hair) (meta-analysis of 13 cohort and case-control studies)³⁰ and cSCC (OR, 14.44; 95% CI, 4.72-44.18 vs black hair) (multicenter case-control study of 3572 patients).³¹ Individuals who report they "burn, never tan" have a higher risk of keratinocyte carcinoma compared with those who report they "tan, never burn" (BCC: OR, 2.03; 95% CI, 1.73-2.38 [meta-analysis of 11 cohort and case-control studies]; cSCC: OR, 2.02; 95% CI, 1.20-3.40 [multicenter case-control study of 3572 patients]).^{30,31} However, individuals of all races, ethnicities, pigmentation characteristics, and skin phototypes can develop keratinocyte carcinoma.^{26,30,32}

Sunburn also increases the risk of keratinocyte carcinomas. A meta-analysis of 8 cohort and case-control studies with 129 525 individuals reported an association with increased BCC risk (for every additional 5 sunburns per decade, relative risk, 1.91; 95% CI, 1.42-2.58).³³ A meta-analysis of 6 cohort and case-control studies with 283 017 individuals reported an association with increased cSCC risk (ORs, 1.51 [95% CI, 1.26-1.81] for medium frequency and 1.69 [95% CI, 1.39-2.06] for high frequency of lifetime painful, blistering, and/or severe sunburns, compared with none).³⁴ Indoor tanning is also associated with increased keratinocyte carcinoma risk. A meta-analysis of 10 cohort and case-control studies with 78 375 individuals reported increased risk of BCC among individuals who ever used indoor tanning compared with those who never used indoor tanning (relative risk, 1.24; 95% CI, 1.00-1.55).³⁵ Another meta-analysis of 9 cohort and case-control studies with 305 360 individuals reported increased risk of cSCC among individuals who ever used indoor tanning (relative risk, 1.58; 95% CI, 1.38-1.81), and the risk of keratinocyte carcinoma was higher among those exposed to indoor tanning before age 50 years and those with more than 10 exposures per year.³⁵ Selection bias is likely in these studies because individuals who indoor tan may also be more likely to have outdoor UV exposure.

Keratinocyte carcinoma incidence is higher among males than females. In US Medicare patients older than 65 years (2009-2018), keratinocyte carcinoma incidence was 18 973 per 100 000 person-years in men vs 7428 per 100 000 person-years in women.²⁶ Based on 2023 data, BCC incidence in the Netherlands was 304.8 per 100 000 person-years in men vs 286.4 per 100 000 person-years in women, and cSCC incidence was 107.6 per 100 000 person-years in men vs 69.5 per 100 000 person-years in women.²⁷ Older age is also associated with increased keratinocyte carcinoma risk: 2023 incidence rates in the Netherlands of BCC were 86.5 per 100 000 person-years in individuals aged 30 to 44 years vs 1221.2 per 100 000 person-years in individuals aged

75 years or older and of cSCC were 2.9 per 100 000 person-years in individuals aged 30 to 44 years vs 622.6 per 100 000 person-years in individuals aged 75 years or older.²⁷

Patients with a history of actinic keratosis are at increased risk of developing keratinocyte carcinoma compared with individuals without actinic keratosis. Actinic keratoses are dysplastic skin lesions that can transform into cSCCs (absolute risk of 0.6% at 1 year; 95% CI, 0.5%-0.8%).³⁶ Although they do not transform into BCCs, their presence is a risk factor for BCC. In a Swedish cohort of 17 651 patients followed up from 2000 to 2014, 21.0% of patients with actinic keratosis developed BCC compared with 4.7% of controls and 18.8% developed cSCC compared with 2.4% of controls.³⁷ In a cohort of 555 945 US Medicare patients (2009-2018) with actinic keratosis compared with 481 024 patients with a benign skin lesion, patients with actinic keratosis had increased risk of keratinocyte carcinoma (HR, 2.20; 95% CI, 2.18-2.22) and an absolute risk of any skin cancer of 28.5% at 5 years.³⁸ In a cohort of 1169 patients from the Netherlands, having 10 or more actinic keratoses was associated with higher keratinocyte carcinoma risk (HR, 2.44; 95% CI, 1.65-3.61) compared with having 1 to 3 actinic keratoses.³⁹

Compared with the general population, patients who are immunosuppressed, especially those with solid organ transplants, are at increased risk of keratinocyte carcinoma, with the risk varying by the organ transplanted, age, sex, and geographical location. The 10-year cumulative incidence of keratinocyte carcinoma among organ transplant recipients is 13% to 52%.⁴⁰ The standardized incidence ratio, which compares the rates of keratinocyte carcinoma in those with organ transplants compared with the general population, is 6.6 for BCC (meta-analysis of 6 cohort studies) and 46 for cSCC (meta-analysis of 5 cohort studies).⁴¹ Mortality rates from cSCC are also increased in solid organ transplant recipients, ranging from 4.9 to 78 per 100 000 person-years.^{42,43} Allogeneic stem cell transplant is associated with increased BCC risk by 3-fold (10-year absolute risk, 5.3%) and increased cSCC risk by 18-fold (10-year absolute risk, 0.8%).⁴⁴ Chronic lymphocytic leukemia is associated with increased BCC risk by 2.6-fold (10-year absolute risk, 8.5%) and increased cSCC risk by 4.4-fold (10-year absolute risk, 5.9%).⁴⁵ Patients with HIV also have an increased risk of keratinocyte carcinoma, with incidence rate ratios of 1.79 (95% CI, 1.43-2.22) for BCC and 5.40 (95% CI, 3.07-9.52) for cSCC in a Danish cohort study that included 25 679 patients with HIV and age- and sex-matched controls.⁴⁶


Clinical Presentation

The **Figure** shows examples of clinical presentations of BCC and cSCC subtypes. **Table 1** summarizes major clinical and epidemiologic characteristics of keratinocyte carcinomas.

Basal Cell Carcinomas

There are 3 common subtypes of BCC. Nodular BCCs, which account for 40% to 70% of BCCs, present as shiny, translucent, or pearly pink raised lesions with a smooth surface, sometimes with visible blood vessels.^{7,47,48} Superficial BCCs (approximately 20%-30%) present as well-defined, red, flat lesions, often with some scale, and may be misdiagnosed as eczema.^{7,47,48} Infiltrative and morpheaform BCCs (approximately 5%-30%) present as scar-like, white or light pink, flat or depressed lesions.^{7,47,48}

Figure. Examples of Clinical Presentations of BCC and cSCC Subtypes



^aImage is from the International Skin Imaging Collaboration (ISIC), courtesy of Hospital Italiano de Buenos Aires, Argentina, licensed under CC-BY.

^bImage is courtesy of the Department of Dermatology, National Cheng Kung University Hospital, Taiwan.

^cImage is courtesy of Archana Singal.

^dImage is from the ISIC, courtesy of the Federal University of Espírito Santo (UFES), Brazil, licensed under CC-BY.

^eImage is courtesy of Megan Rogge.

^fImage is courtesy of Yung-Tsu Cho.

BCCs can be pigmented (have increased melanin pigment) and include brown, blue, or black colors; pigmentation is more common in BCCs in patients with darker skin pigmentation.^{55,56} BCCs most commonly occur on the head and neck (40%-64%, with 28%-54% on the face) and trunk (15%-35%).⁶⁻⁹ BCCs can be asymptomatic, although approximately 37% of BCCs bleed, 23% to 33% itch, and 16% to 18% cause tenderness or discomfort.⁵⁷⁻⁵⁹

Cutaneous Squamous Cell Carcinomas

Actinic keratoses can be precursors to cSCCs and present on sun-exposed areas as rough or scaly lesions that are usually red or pink but can be brown.^{8,60} cSCCs in situ (40% of cSCCs) involve only the epidermis or uppermost layer of the skin and typically present as red,

scaly, flat or thinly raised lesions.⁴⁹ Invasive cSCCs (60% of cSCCs) extend deeper than the epidermis and appear as red, firm, raised lesions, often with thick scaling or erosions.⁴⁹ cSCCs most commonly occur on the head and neck (35%-45%, with 23%-36% on the face) and the upper extremities (25%-35%).^{6,8,9} Approximately 24% of cSCCs bleed, 44% itch, and 40% to 41% cause tenderness or discomfort.^{58,59}

Assessment and Diagnosis

Clinical assessment for keratinocyte carcinoma is performed with a visual skin examination, preferably by a trained clinician with expertise

Table 1. Major Clinical and Epidemiologic Characteristics of Keratinocyte Carcinomas

	Basal cell carcinoma (BCC)	Cutaneous squamous cell carcinoma (cSCC)
Clinical features ^a	<ul style="list-style-type: none"> Most common on the head and neck (40%-64%) and trunk (15%-35%)⁶⁻⁹ Asymptomatic or symptoms of bleeding, itching, or pain Nodular BCC (40%-70%): shiny, translucent or pearly pink, raised lesion with a smooth surface, sometimes with visible blood vessels^{7,47,48} Superficial BCC (20%-30%): well-defined, red, flat lesion, often with some scale^{7,47,48} Infiltrative and morpheaform BCCs (5%-30%): scar-like, white or light pink, flat or depressed lesion^{7,47,48} 	<ul style="list-style-type: none"> Most common on the head and neck (35%-45%) and upper extremities (25%-35%)^{6,8,9} Asymptomatic or symptoms of bleeding, itching, or pain cSCC in situ (40%): red, scaly, flat or thinly raised lesion⁴⁹ Invasive cSCC (60%): red, firm, raised lesion, often with thick scaling or erosions⁴⁹
Incidence	305 per 100 000 person-years in men and 286 per 100 000 person-years in women (the Netherlands, 2023) ²⁷	108 per 100 000 person-years in men and 69.7 per 100 000 person-years in women (the Netherlands, 2023) ²⁷
	5 434 193 treated keratinocyte carcinomas in 3 315 554 patients annually (US, 2012) ¹	
Risk of metastasis	0.004% (Denmark, 14-year cumulative incidence) ¹⁴	1.2%-1.9% (United Kingdom, ¹⁶ within a mean of 6.5 years, and the Netherlands, 10-year cumulative incidence, ¹⁸ respectively)
Mortality	0.08 per 100 000 person-years ¹⁹	0.72 per 100 000 person-years (Global Burden of Disease, 2021; rates per 100 000 person-years were 3.19 in Australia and New Zealand, 1.69 in Western Europe, and 1.53 in the US, Canada, and Greenland) ²¹
Risk factors	<ul style="list-style-type: none"> Pigmentation characteristics (eg, lighter pigmentation, red hair) Skin phototype (eg, skin response to sun exposure, sometimes described using the Fitzpatrick scale)²⁹ UV exposure (natural sunlight, sunburn, and indoor tanning) Male sex Older age History of actinic keratosis History of keratinocyte carcinoma Organ transplant Allogeneic stem cell transplant HIV Genetic syndromes^{50,b} Smoking (cSCC only)⁵¹ Human papillomavirus (nonanogenital; cSCC only)⁵² Chronic wounds or chronic skin inflammation (cSCC only)⁵³ Chemical exposures (cSCC only)^{54,c} 	

^a Less common (<10%) types of BCC include sclerosing, micronodular, infundibulocystic, fibroepithelioma of Pinkus, keratotic, and basosquamous.

^b Genetic syndromes include basal cell nevus syndrome (BCC), oculocutaneous albinism (BCC and cSCC), epidermolysis bullosa variants (cSCC), Kindler syndrome (BCC and cSCC), epidermodysplasia verruciformis (cSCC), Ferguson-Smith syndrome (cSCC), Hurler syndrome (cSCC), Fanconi anemia (cSCC), Rothmund-Thomson syndrome (BCC and cSCC), Bloom syndrome (BCC and cSCC), and dyskeratosis congenita (cSCC).

^c Chemical exposures include arsenic, polycyclic aromatic hydrocarbons, and nitrosamines.

in dermoscopy (use of a dermatoscope, a handheld instrument with a magnifying lens and transilluminating light source). For diagnosis of BCC, dermoscopy has a sensitivity of 91% and specificity of 95% among experts⁶¹ (insufficient data for cSCC).⁶² The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) suggest a full-body skin examination for patients being evaluated for keratinocyte carcinoma because they may have additional skin cancers on other parts of their body.^{63,64}

The diagnosis of keratinocyte carcinoma requires pathologic evaluation of a shave biopsy or punch biopsy (see related video). Shave biopsies use a flexible blade to remove a bowl-shaped slice of the epidermis and dermis, do not include subcutaneous fat, and do not require sutures. Punch biopsies use an instrument with a hollow, sharp end to remove a small circular piece of skin, extend to the subcutaneous fat, and are often closed with sutures.

Treatment

Risk Stratification

BCC is classified as being at low or high risk of recurrence and cSCC is classified as being at low, high, or very high risk of recurrence (risk stratification based on location, size, status as primary vs recurrent, histopathologic features, history of radiation or inflammatory

process, and patient immunosuppression) (Table 2 and Table 3), which helps guide choice of treatment modality (Table 4).

Surgical Treatments

Standard Excision

Standard excision is appropriate for low-risk keratinocyte carcinomas and is the most common treatment.¹¹ Standard excision is an in-office procedure using local anesthetic in which the tumor and a 4- to 6-mm margin of uninvolved skin around the tumor or biopsy site are removed with a depth that extends to subcutaneous fat, followed by suturing to repair the defect. After the procedure, standard histopathologic assessment is performed, which visualizes only 1% to 2% of the total surgical margin because the surgical specimen is sampled at intervals rather than the entire peripheral and deep margins.⁶⁷ In a network meta-analysis of 16 RCTs with follow-up times of 3 months to 10 years that included 2204 BCCs, local recurrence rates were 3.3% (95% CI, 1.3%-7.8%).¹³ In a meta-analysis of 8 cohort and case-control studies of 736 patients with cSCC, local recurrence rates at 2 to 5 years of follow-up were 5.0% (95% CI, 2.3%-8.3%).¹¹

Mohs Surgery

Mohs surgery, typically performed by dermatologists with specialized training, is an in-office procedure using local anesthetic in which

Table 2. Basal Cell Carcinoma Risk Stratification for Determination of Treatment per National Comprehensive Cancer Network Guidelines^{63,a}

	Risk of posttreatment recurrence	
	Low	High
Location and size	Trunk, extremities; <2 cm	<ul style="list-style-type: none"> • Trunk, extremities; ≥2 cm • Head, neck, hands, feet, pretibial, and anogenital area (any size)
Primary vs recurrent	Primary	Recurrent
Borders	Well defined	Ill defined
Immunosuppression	Absent	Present
Site of previous radiation	Absent	Present
Histopathologic subtype	<ul style="list-style-type: none"> • Nodular • Superficial • Keratotic • Infundibulocystic • Fibroepithelioma of Pinkus 	<ul style="list-style-type: none"> • Morpheaform • Sclerosing • Infiltrative • Micronodular • Basosquamous
Perineural involvement	Absent	Present

^a Reproduced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Basal Cell Skin Cancer, version 2.2025.⁶³

Table 3. Cutaneous Squamous Cell Carcinoma Risk Stratification for Determination of Treatment per National Comprehensive Cancer Network Guidelines^{64,a}

	Risk of posttreatment recurrence, metastases, or death		
	Low	High	Very high
Location and size	Trunk, extremities; ≤2 cm	<ul style="list-style-type: none"> • Head, neck, hands, feet, pretibial, and anogenital (any size) • Trunk, extremities; >2 cm to ≤4 cm 	>4 cm (any location)
Primary vs recurrent	Primary	Recurrent	
Borders	Well defined	Ill defined	
Immunosuppression	Absent	Present	
Site of previous radiation or chronic inflammatory process	Absent	Present	
Rapid growth	Absent	Present	
Neurologic symptoms	Absent	Present	
Histopathologic features	Well or moderately differentiated	Histologic subtype: acantholytic, adenosquamous, metaplastic, or desmoplastic in any portion of the tumor	<ul style="list-style-type: none"> • Poorly differentiated • Histologic subtype: acantholytic, adenosquamous, metaplastic, or desmoplastic in any portion of the tumor
Depth of invasion	<2 mm and no invasion of subcutaneous fat	2–6 mm and no invasion beyond subcutaneous fat	>6 mm or invasion beyond subcutaneous fat
Perineural involvement	Absent	Present	Tumor cells within the nerve sheath of a nerve lying deeper than the dermis or measuring ≥0.1 mm
Lymphatic or vascular involvement	Absent	Absent	Present

^a Reproduced with permission from the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Squamous Cell Skin Cancer, version 2.2025.⁶⁴

the visible tumor is removed, followed by a thin layer (1–2 mm) of surrounding tissue from under and circumferentially around the wound. This thin layer is processed for immediate pathologic evaluation by the surgeon using sections that allow for 100% of the surgical margin to be examined pathologically,⁶⁷ typically while the patient waits. If tumor is present in the surgical margin, another thin layer of tissue is excised from the relevant area until the tumor is completely removed, after which the defect is repaired. Mohs surgery is recommended for high-risk BCC and high-risk and very high-risk cSCC by the American Academy of Dermatology^{10,12} and the NCCN Guidelines.^{63,64} In the aforementioned network meta-analysis of 16 RCTs, local recurrence rates of BCC after Mohs surgery were 3.8% (95% CI, 0.7%–18.9%).¹³ In meta-analysis of 7 cohort and case-control studies that included 1116 patients with cSCC, local recur-

rence rates after Mohs surgery at 2 to 5 years of follow-up were 2.8% (95% CI, 2.0%–3.9%).¹¹

Curettage and Electrodesiccation

Curettage and electrodesiccation is an in-office procedure using local anesthetic in which the visible tumor and a 2- to 3-mm margin is surgically scraped away using a curette and the wound base is cauterized. Curettage and electrodesiccation does not include pathologic evaluation and is appropriate for selected low-risk keratinocyte carcinomas on areas that do not have terminal hair (eg, not on the hair-bearing scalp, beard area, underarms, pubic region).^{63,73,74} Curettage and electrodesiccation may be associated with longer healing times and inferior cosmetic outcomes compared with standard excision or Mohs surgery and is typically avoided in visible areas such as the face.⁷⁵ Local

Table 4. Major Treatments Available for Keratinocyte Carcinomas

Treatment type	Indications	Description/mechanism	Efficacy	Risks/adverse effects
Standard surgical treatment modalities				
Surgical excision	First-line treatment for low-risk keratinocyte carcinomas ^{10,12,63-65}	A 4- to 6-mm margin of clinically uninvolved skin around the tumor or biopsy site is removed down to subcutaneous fat.	Local recurrence rates: • 3.3% (95% CI, 1.3%-7.8%) for BCC ¹³ • 5.0% (95% CI, 2.3%-8.3%) for cSCC ¹¹	Pain, bleeding, scarring, postoperative hemorrhage (3%), infection (2%), vasovagal syncope (1%), nerve damage ⁶⁶
Mohs surgery	First-line treatment for high-risk keratinocyte carcinomas ^{10,12,63-65}	Visible tumor is removed, followed by a thin layer of surrounding tissue from under and circumferentially around the wound. 100% of the surgical margin is then immediately examined pathologically using horizontal sections while the patient waits. ⁶⁷ If cancer is in the surgical margin, another thin layer of tissue is removed only from around the area where the cancer was seen on pathology.	Local recurrence rates: • 3.8% (95% CI, 0.7%-18.2%) for BCC ¹³ • 2.8% (95% CI, 2.0%-3.9%) for cSCC ¹¹	Pain, bleeding, scarring, infection (0.44%), dehiscence or necrosis (0.14%), postoperative bleeding and hematoma (0.11%), nerve damage ⁶⁸
Curettage and electrodesiccation	Low-risk keratinocyte carcinomas not on terminal hair-bearing skin and not in cosmetically sensitive areas ^{10,12,63,64}	Tumor is scraped away using a curette, then wound base is cauterized. This can be repeated 3 times during the procedure.	Local recurrence rates: • 5.9% (95% CI, 0.7%-34.9%) for BCC ¹³ • 2.0% (95% CI, 1.1%-3.0%) for cSCC ⁶⁹	Pain, bleeding, scarring, dyspigmentation ⁷⁰
Nonsurgical approaches to consider in selected situations				
Topical fluorouracil, 5%	<ul style="list-style-type: none"> FDA approved for superficial BCCs Off-label for cSCCs 	<ul style="list-style-type: none"> Inhibits DNA synthesis Twice-daily application for 3-6 weeks 	Local recurrence rates: • 24.7% (95% CI, 7.1%-58.4%) for BCC ¹³ • 16.1% (95% CI, 10.3%-21.8%) for cSCC (invasive and in situ) ⁶⁹	Erythema (33%-97%), pain (33%-50%), dermatitis (20%), pruritus (17%), scarring (9%-16%), crusting/scabbing (13%), burning/stinging (7%), ulceration (4%-9%), erosion (6%), hyperpigmentation (3%) ⁷¹
Topical imiquimod, 5%	<ul style="list-style-type: none"> FDA approved for superficial BCCs ≤2 cm on trunk, neck, and extremities Off-label for cSCCs 	<ul style="list-style-type: none"> Immune response modifier, induces production of cytokines, leading to apoptosis of tumor cells Once-daily treatment 5 times a week for 6 weeks or longer¹⁰ 	Local recurrence rates: • 14.1% (95% CI, 5.4%-32.4%) ¹³ for BCC • 26.6% (95% CI, 16.9%-36.4%) for cSCC (invasive and in situ) ⁶⁹	Erythema (63%-100%), edema (3%-92%), pruritus (16%-67%), hypopigmentation (9%-67%), crusting/scabbing/scaling (52%-65%), erosion/ulceration (25%-53%), burning (6%-35%), pain (3%-35%), blisters (3%-17%), scarring (15%), flu-like symptoms (9%) ⁷¹
Photodynamic therapy (topical)	Selected low-risk keratinocyte carcinomas	In-office application of a photosensitizer, incubation period, then irradiation with a specific light source	Local recurrence rates: • 17.8% (95% CI, 9.1%-31.8%) or 16.9% (95% CI, 7.4%-34.4%) for BCC ¹³ • 29.0% (95% CI, 25.0%-33.0%) for cSCC (invasive and in situ) ⁶⁹	Photosensitivity, need for light avoidance and photoprotection for 48 hours, pain (99%), erythema (92%), edema (35%), exudation (23%), hyperpigmentation (27%) ^{10,72}
Radiation therapy	When surgery is not feasible, is contraindicated, or is not preferred by the patient after a discussion of risks and benefits ^{10,12}	<ul style="list-style-type: none"> External-beam radiation therapy Brachytherapy (radiation source placed close to or in direct contact with keratinocyte carcinoma; can be done in office) Typically involves treatments 5 times per week for 3-7 weeks 	Local recurrence rates: • 3.2% (95% CI, 0.6%-16.1%) for external-beam radiation in BCC ¹³ • 6.4% (95% CI, 3.0%-11.0%) for external-beam radiation and 5.2% (95% CI, 1.6%-10.5%) for brachytherapy for cSCC ¹¹	Local skin toxicities (eg, erythema, desquamation, fibrosis, atrophy), cartilage necrosis, and increased difficulty of treating keratinocyte carcinoma recurrences (increased surgical complexity in previously radiated skin) ¹⁰
Active surveillance/watchful waiting	Low-risk keratinocyte carcinomas in patients with limited life expectancy or who prefer active surveillance/watchful waiting	No initial treatment; close monitoring	Not applicable	New symptoms, tumor growth, requirement of more invasive treatment if treatment pursued ⁵⁷

Abbreviations: BCC, basal cell carcinoma; cSCC, cutaneous squamous cell carcinoma; FDA, US Food and Drug Administration.

recurrence rates after curettage and electrodesiccation are 5.9% for BCC (95% CI, 0.7%-34.9%) (network meta-analysis of 16 RCTs)¹³ and 2.0% for cSCC (1.1%-3.0%) (meta-analysis of 13 single-group observational studies with 2352 cSCCs [invasive and in situ]).⁶⁹

All surgical treatments for keratinocyte carcinoma cause pain (days to weeks) and scarring, although the scarring varies with procedural and individual patient factors. Other adverse events such as infection, postoperative hemorrhage, or wound dehiscence occur in approximately 2% of cases.⁷⁶

Nonsurgical Treatments

For patients in whom surgery is not feasible or is contraindicated (eg, large keratinocyte carcinomas for which surgery carries functional complications, such as facial palsy) or is not preferred (eg, patients who strongly wish to avoid surgery), the NCCN Guidelines^{63,64} and/or American Academy of Dermatology guidelines^{10,12} suggest considering nonsurgical approaches such as photodynamic therapy, topical medications, radiation therapy, and active surveillance.

Photodynamic therapy is an in-office treatment consisting of topical application of a photosensitizer (commonly aminolevulinic acid or methyl aminolevulinate), an incubation period of 30 minutes to 3 hours, then irradiation with a specific light source (commonly blue light in the 410- to 420-nm range or red light at 630 nm). Photodynamic therapy, which is appropriate for low-risk keratinocyte carcinomas, is associated with BCC recurrence rates of 17.8% (95% CI, 9.1%-31.8%) or 16.9% (95% CI, 7.4%-34.4%), depending on photosensitizer (meta-analysis of 16 RCTs).¹³ Photodynamic therapy used for cSCC is associated with recurrence rates of 29.0% (95% CI, 25.0%-33.0%) (meta-analysis of 99 single-group observational studies with 3798 cSCCs [invasive and in situ]).⁶⁹

Topical therapy (eg, cream applied by patients at home) for treatment of keratinocyte carcinoma includes topical imiquimod, an immunomodulator, and topical fluorouracil, a chemotherapy. For BCC, topical imiquimod 5 times per week for 6 weeks is approved by the US Food and Drug Administration (FDA) for superficial BCCs of 2 cm or smaller on the trunk, neck, and extremities and is associated with recurrence rates of 14.1% (95% CI, 5.4%-32.4%) (meta-analysis of 16 RCTs).¹³ Topical fluorouracil twice daily for at least 3 to 6 weeks is approved by the FDA for superficial BCC, with recurrence rates of 24.7% (95% CI, 7.1%-58.4%) (meta-analysis of 16 RCTs).¹³ For cSCC, topical therapies are off-label. Topical imiquimod has cSCC recurrence rates of 16.1% (95% CI, 10.3%-21.8%) (meta-analysis of 26 single-group observational studies with 286 cSCCs [invasive and in situ]).⁶⁹ Topical fluorouracil has cSCC recurrence rates of 26.6% (95% CI, 16.9%-36.4%) (meta-analysis of 21 single-group observational studies with 430 cSCCs [invasive and in situ]).⁶⁹ Adverse events from imiquimod and fluorouracil include local skin reactions, such as erythema, swelling, erosions, crust, vesicles, pain, and itching at the site of administration, and are moderate to severe in 15% to 60% of patients. Approximately 2% to 4% of patients using imiquimod and 5% of patients using fluorouracil discontinue therapy due to adverse events.^{71,77,78} Adverse events associated with imiquimod may also include flu-like symptoms (eg, headache, myalgia, fatigue) in 1% to 8% of patients.⁷⁷⁻⁷⁹

Radiation therapy for definitive treatment of keratinocyte carcinoma consists of external-beam radiation or brachytherapy and typically involves 3 to 7 weeks of 5 daily treatments per week. Adverse events associated with external-beam radiation or brachytherapy include local skin toxicities (eg, erythema, desquamation, fibrosis, atrophy), cartilage necrosis, and increased difficulty of treating keratinocyte carcinoma recurrences (increased surgical complexity in previously radiated skin).¹⁰ External-beam radiation therapy has recurrence rates for BCC of 3.2% (95% CI, 0.6%-16.1%) (network meta-analysis of 16 RCTs)¹³ and for cSCC of 6.4% (95% CI, 3.0%-11.0%) (meta-analysis of 7 cohort and case-control studies with 24-144 months of follow-up in 761 patients).¹¹ Brachytherapy has recurrence rates for cSCC of 5.2% (95% CI, 1.6%-10.5%) (meta-analysis of 6 cohort and case-control studies with 9.6-55 months of follow-up with 364 patients).¹¹ Radiation therapy as an adjuvant following surgery should be considered for recurrent cSCC that is resected with margins free of tumor when the lesion is large (≥ 4 cm), is deeply invasive (>6 mm), or has extensive microscopic perineural invasion or clinical nerve involvement.⁸⁰

Active surveillance (no initial treatment with clinical monitoring) is a potential option for patients with low-risk keratinocyte carcinomas who are older or have limited life expectancy. In 1 prospec-

tive cohort of 89 patients with both low- and high-risk BCC who chose active surveillance, 8% developed new tumor symptoms such as bleeding and 38% stopped active surveillance and were treated (more invasive treatment required in only 2.8%).⁵⁷ In 2 retrospective cohorts of 148 cSCCs and 411 cSCCs in situ that appeared clinically resolved after biopsy and were managed by clinical monitoring, 1.4% of cSCCs (2/148; median follow-up, 35 months) and 4.1% of cSCCs in situ (17/411; median follow-up, 41 months) recurred locally.^{81,82}

Prognosis

Prognosis for most patients with keratinocyte carcinomas is excellent, with low recurrence rates using in-office surgical treatments (Table 4). Local keratinocyte carcinoma recurrences are treated as high-risk tumors and are treated with Mohs surgery or reexcision with wider surgical margins.^{63,64} Metastases were reported in 0.004% of 126 627 patients with BCCs in Denmark,¹⁴ in 1.2% of 1122 patients with cSCCs in the UK,¹⁶ and in 1.9% of 11 137 patients with cSCCs in the Netherlands.¹⁸ Metastasis sites of cSCC include regional lymph nodes (52%), the parotid gland (44%), and skin (12%); distant metastases are uncommon (2%).¹⁸ In a Netherlands cancer registry cohort of 217 metastatic cSCCs, most metastases occurred within 4 years of primary cSCC diagnosis (78%).¹⁸ Systemic therapies to treat metastatic disease are outside the scope of this Review.

Screening and Surveillance

Screening for the General Population

The 2023 US Preventive Services Task Force determined that evidence is insufficient to assess the benefits and harms of skin cancer screening (including keratinocyte carcinomas and melanoma) in the general population.⁸³ The American Academy of Dermatology encourages everyone to perform regular skin self-examinations,⁸⁴ although it is not an official guideline.

Risk Stratification and Screening for Solid Organ Transplant Recipients

For solid organ transplant recipients, the risk of skin cancer (including keratinocyte carcinomas and melanoma) can be calculated using the externally validated Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC), which incorporates high-risk characteristics, including White race, pretransplant history of skin cancer, male sex, and heart or lung transplant.^{85,86} Solid organ transplant recipients are grouped into 4 risk categories, with initial skin cancer screening recommendations ranging from within 6 months of transplant for very high risk (5-year cumulative skin cancer incidence, 45%) to within 10 years of transplant for low risk (5-year cumulative incidence, 1%).⁸⁵

Surveillance After Keratinocyte Carcinoma Diagnosis

Compared with individuals without a history of keratinocyte carcinoma, patients diagnosed with keratinocyte carcinoma are at higher risk of new primary keratinocyte carcinomas as well as at higher risk of melanomas. A prospective cohort study of 1426 patients with keratinocyte carcinoma reported a 40.7% (95% CI, 36.5%-45.2%) absolute risk of developing a new primary keratinocyte carcinoma

at 5 years.⁸⁷ The risk of melanoma in a cohort of 153 576 individuals who were diagnosed with keratinocyte carcinoma and self-identified as White was 116 per 100 000 person-years for men and 79 per 100 000 person-years for women.⁸⁸

Full-body skin examinations are recommended by the NCCN Guidelines after keratinocyte carcinoma: for patients with BCCs, every 6 to 12 months for the first 5 years and then annually,⁶³ and for patients with low-risk, local cSCCs, every 3 to 12 months for the first 2 years, then every 6 to 12 months for the next 3 years, then annually.⁶⁴ However, patients with high-risk and metastatic cSCCs should be examined more frequently.⁶⁴

Prevention

Primary prevention of keratinocyte carcinoma centers on sun protection, which includes shade-seeking behavior, decreased exposure during peak UV hours, sun-protective clothing and hats, sunscreen use, and avoidance of indoor tanning.⁸⁹ However, few studies prospectively evaluate the efficacy of sun protection strategies for skin cancer prevention. One large RCT in the 1990s in Australia compared daily use of sunscreen with a sun protection factor (SPF) of 16 with discretionary sunscreen use for 4.5 years and showed a reduced risk of cSCC from 1587 per 100 000 person-years (discretionary use group) to 953 per 100 000 person-years (daily use group; rate ratio, 0.62; 95% CI, 0.38-0.99) 8 years after the intervention ended. That RCT also showed a decreased risk of invasive melanoma 10 years after the intervention ended (HR, 0.27; 95% CI, 0.08-0.97; 11/809 in discretionary use group and 3/812 in daily use group) but did not show a decreased risk of BCC.^{90,91} In organ transplant recipients with actinic keratoses, a prospective matched case-control study that provided the intervention group with free sunscreen reported fewer cSCCs in those provided free sunscreen vs controls (0/60 vs 8/60, respectively; $P < .01$).⁹² The American Academy of Dermatology recommends use of broad-spectrum protection (UV-A and UV-B) sunscreens with an SPF of 30 or above, reapplied every 2 hours during UV exposure.⁹³

Actinic keratosis lesions are typically treated with the goal of preventing cSCC. Actinic keratosis treatments include in-office liquid nitrogen cryotherapy, topical medications such as fluorouracil or imiquimod, and photodynamic therapy.⁹⁴

For patients with a history of keratinocyte carcinoma, over-the-counter nicotinamide (a form of vitamin B₃; 500 mg twice

daily) may prevent future skin cancers. In an RCT of 386 immunocompetent patients with a history of at least 2 keratinocyte carcinomas in the prior 5 years, there were 1.8 new keratinocyte carcinomas per patient in the nicotinamide group and 2.4 per patient in the placebo group over 12 months (23% decrease; 95% CI, 4%-38%).⁹⁵ However, 2 RCTs of nicotinamide use in organ transplant patients have not shown reductions in skin cancer risk.^{96,97} Topical fluorouracil has shown benefit for chemoprevention of cSCC. A trial that randomized patients with at least 2 keratinocyte carcinomas in the prior 5 years to topical fluorouracil on the face and ears as a prophylactic chemopreventive vs placebo reported a 75% (95% CI, 35%-91%; $P = .02$) cSCC risk reduction (5/468 [1.1%] in fluorouracil group and 20/464 [4.3%] in control group) at 1 year.⁹⁸ For organ transplant recipients, oral acitretin (a prescription vitamin A derivative) may be beneficial for chemoprevention (56% reduction in keratinocyte carcinomas in a meta-analysis of 3 RCTs and 1 observational study with 103 patients; confidence intervals and P values not provided).⁹⁹ However, acitretin has adverse effects such as dryness of skin and mucosal membranes (mucocutaneous xerosis) and teratogenicity. In addition, patients taking this medication need laboratory testing every 3 months (lipids, liver function, blood cell count, creatinine) to monitor for adverse effects.⁹⁹

Limitations

This Review has limitations. First, some relevant articles may have been missed. Second, formal evaluation of the quality of the included articles was not performed. Third, many studies refer to keratinocyte carcinomas as a single outcome rather than separating data for BCCs and cSCCs.

Conclusions

Keratinocyte carcinomas, composed of BCCs and cSCCs, are the most common cancer in the US, with an estimated 5.4 million keratinocyte carcinomas diagnosed annually. Most keratinocyte carcinomas are effectively treated with in-office surgical procedures. Patients with keratinocyte carcinomas are recommended to undergo a skin examination at least annually due to their high risk of developing additional skin cancers.

ARTICLE INFORMATION

Accepted for Publication: September 15, 2025.

Published Online: October 30, 2025.
doi:10.1001/jama.2025.18749

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported in part by grant RR190078 from the Cancer Prevention and Research Institute of Texas to Dr Wehner. Dr Wehner is a Cancer Prevention and Research Institute of Texas Scholar in Cancer Research and is supported by grant K08 CA263298 from the National Cancer Institute.

Role of the Funder/Sponsor: The supporters had no role in the preparation, review, or approval of

the manuscript or decision to submit the manuscript for publication.

Additional Contributions: I acknowledge research medical librarian Travis Holder, MSLS, MA, research program manager Candice Hinkston, MPH, and postdoctoral fellows Gabriella Alvarez, MD, and Isaac Weber, MD (all with University of Texas MD Anderson Cancer Center), for assistance with the literature search and citations. They were not compensated outside of their regular employment.

Submissions: We encourage authors to submit papers for consideration as a Review. Please contact Kristin Walter, MD, at kristin.walter@jamanetwork.org.

REFERENCES

1. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. *JAMA Dermatol*. 2015;151(10):1081-1086. doi:10.1001/jamadermatol.2015.1187
2. US Cancer Statistics Working Group. US cancer statistics data visualizations tool. Centers for Disease Control and Prevention and National Cancer Institute. Updated June 2024. Accessed September 1, 2024. <https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/>
3. Hu W, Fang L, Ni R, Zhang H, Pan G. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted

- level in 25 years. *BMC Cancer*. 2022;22(1):836. doi:10.1186/s12885-022-09940-3
4. Rogers H, Beveridge M, Puente J, Wixson S, Loy B, Happe LE. Incidence of nonmelanoma skin cancer in the United States population aged 65 years and older, 2014. *J Am Acad Dermatol*. 2021;85(3):741-743. doi:10.1016/j.jaad.2019.08.079
 5. Kwiatkowska M, Ahmed S, Ardern-Jones M, et al. An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013-2018. *Skin Health Dis*. 2021;1(4):e61. doi:10.1002/ski.2.61
 6. Navsaria LJ, Li Y, Tripathy S, et al. Anatomic locations of procedurally treated keratinocyte carcinomas in the US Medicare population. *JAMA Dermatol*. 2023;159(6):643-647. doi:10.1001/jamadermatol.2023.0611
 7. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. *Br J Dermatol*. 2006;155(2):401-407. doi:10.1111/j.1365-2133.2006.07234.x
 8. Kim K, Kim JW, Santos I, Oakley A. Body site locations of basal cell carcinoma, squamous cell carcinoma and actinic keratosis in patients referred to the Waikato District Health Board teledermatology clinic. *J Prim Health Care*. 2022;14(1):80-86. doi:10.1071/HC21115
 9. Subramaniam P, Olsen CM, Thompson BS, Whiteman DC, Neale RE; QSkin Sun and Health Study Investigators. Anatomical distributions of basal cell carcinoma and squamous cell carcinoma in a population-based study in Queensland, Australia. *JAMA Dermatol*. 2017;153(2):175-182. doi:10.1001/jamadermatol.2016.4070
 10. Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P; Work Group; Invited Reviewers. Guidelines of care for the management of basal cell carcinoma. *J Am Acad Dermatol*. 2018;78(3):540-559. doi:10.1016/j.jaad.2017.10.006
 11. Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. *BMJ*. 2013;347:f6153. doi:10.1136/bmj.f6153
 12. Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P; Work Group; Invited Reviewers. Guidelines of care for the management of cutaneous squamous cell carcinoma. *J Am Acad Dermatol*. 2018;78(3):560-578. doi:10.1016/j.jaad.2017.10.007
 13. Drucker AM, Adam GP, Rofeberg V, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. *Ann Intern Med*. 2018;169(7):456-466. doi:10.7326/M18-0678
 14. Nguyen-Nielsen M, Wang L, Pedersen L, et al. The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010. *Eur J Dermatol*. 2015;25(5):463-468. doi:10.1684/ejd.2015.2546
 15. Mitsizis A, Beatson M, Weinstock MA. Keratinocyte carcinoma mortality in the United States as reported in death certificates, 2011-2017. *Dermatol Surg*. 2020;46(9):1135-1140. doi:10.1097/DSS.0000000000002261
 16. Nelson TG, Ashton RE. Low incidence of metastasis and recurrence from cutaneous squamous cell carcinoma found in a UK population: do we need to adjust our thinking on this rare but potentially fatal event? *J Surg Oncol*. 2017;116(6):783-788. doi:10.1002/jso.24707
 17. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. *J Am Acad Dermatol*. 2013;68(6):957-966. doi:10.1016/j.jaad.2012.11.037
 18. Tokez S, Wakkee M, Kan W, et al. Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: a nationwide cancer registry study. *J Am Acad Dermatol*. 2022;86(2):331-338. doi:10.1016/j.jaad.2021.09.067
 19. Lewis KG, Weinstock MA. Nonmelanoma skin cancer mortality (1988-2000): the Rhode Island follow-back study. *Arch Dermatol*. 2004;140(7):837-842. doi:10.1001/archderm.140.7.837
 20. Czarnecki D. Mortality from nonmelanoma skin cancer in Australia from 1971 to 2021. *Cancers (Basel)*. 2024;16(5):867. doi:10.3390/cancers16050867
 21. Institute for Health Metrics and Evaluation. Global Burden of Disease results. Published 2021. Accessed February 24, 2025. <https://vizhub.healthdata.org/gbd-results/>
 22. Jayaraman SS, Rayhan DJ, Hazany S, Kolodney MS. Mutational landscape of basal cell carcinomas by whole-exome sequencing. *J Invest Dermatol*. 2014;134(1):213-220. doi:10.1038/jid.2013.276
 23. Chang D, Shain AH. The landscape of driver mutations in cutaneous squamous cell carcinoma. *NPJ Genom Med*. 2021;6(1):61. doi:10.1038/s41525-021-00226-4
 24. National Toxicology Program, US Department of Health and Human Services. *15th Report on Carcinogens*. Published 2021. Accessed September 4, 2024. <https://ntp.niehs.nih.gov/go/roc15>
 25. International Agency for Research on Cancer. *IARC Monographs on the Evaluation of Carcinogenic Hazards to Humans, No. 100D*. Published 2012. Accessed September 4, 2024. <https://monographs.iarc.who.int/>
 26. Navsaria LJ, Li Y, Tripathy S, et al. Keratinocyte carcinoma incidence by race and ethnicity in older adults with Medicare coverage. *JAMA Dermatol*. 2024;160(1):109-111. doi:10.1001/jamadermatol.2023.4643
 27. Integraal Kankercentrum Nederland. NCR data and figures. Updated October 18, 2022. Accessed April 11, 2025. <https://www.iknl.nl/en/ncr/ncr-data-figures>
 28. Lukowiak TM, Aizman L, Perz A, et al. Association of age, sex, race, and geographic region with variation of the ratio of basal cell to cutaneous squamous cell carcinomas in the United States. *JAMA Dermatol*. 2020;156(11):1192-1198. doi:10.1001/jamadermatol.2020.2571
 29. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. *Arch Dermatol*. 1988;124(6):869-871. doi:10.1001/archderm.1988.01670060015008
 30. Khalesi M, Whiteman DC, Tran B, Kimlin MG, Olsen CM, Neale RE. A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin. *Cancer Epidemiol*. 2013;37(5):534-543. doi:10.1016/j.canep.2013.05.008
 31. Rosso S, Zanetti R, Martinez C, et al. The multicentre south European study "Helios"; II: different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. *Br J Cancer*. 1996;73(11):1447-1454. doi:10.1038/bjc.1996.275
 32. Krickler A, Armstrong BK, English DR, Heenan PJ. Pigmentary and cutaneous risk factors for non-melanocytic skin cancer—a case-control study. *Int J Cancer*. 1991;48(5):650-662. doi:10.1002/ijc.2910480504
 33. Lashway SG, Worthen ADM, Abuasbeh JN, et al. A meta-analysis of sunburn and basal cell carcinoma risk. *Cancer Epidemiol*. 2023;85:102379. doi:10.1016/j.canep.2023.102379
 34. Weber I, Liao K, Dang T, Shah M, Wehner MR. Sunburn and cutaneous squamous cell carcinoma: a meta-analysis. *JAMA Dermatol*. Published online September 24, 2025. doi:10.1001/jamadermatol.2025.3473
 35. An S, Kim K, Moon S, et al. Indoor tanning and the risk of overall and early-onset melanoma and non-melanoma skin cancer: systematic review and meta-analysis. *Cancers (Basel)*. 2021;13(23):5940. doi:10.3390/cancers13235940
 36. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF; Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. *Cancer*. 2009;115(11):2523-2530. doi:10.1002/cncr.24284
 37. Guorgis G, Anderson CD, Lyth J, Falk M. Actinic keratosis diagnosis and increased risk of developing skin cancer: a 10-year cohort study of 17,651 patients in Sweden. *Acta Derm Venereol*. 2020;100(8):adv00128. doi:10.2340/00015555-3486
 38. Mohr C, Li Y, Navsaria LJ, et al. Skin cancers in Medicare beneficiaries with actinic keratoses. *JAMA Dermatol*. 2023;159(12):1368-1372. doi:10.1001/jamadermatol.2023.4266
 39. Tokez S, Alblas M, Nijsten T, Pardo LM, Wakkee M. Predicting keratinocyte carcinoma in patients with actinic keratosis: development and internal validation of a multivariable risk-prediction model. *Br J Dermatol*. 2020;183(3):495-502. doi:10.1111/bjd.18810
 40. Madeleine MM, Patel NS, Plasmeijer EI, et al; Keratinocyte Carcinoma Consortium (KeraCon) Immunosuppression Working Group. Epidemiology of keratinocyte carcinomas after organ transplantation. *Br J Dermatol*. 2017;177(5):1208-1216. doi:10.1111/bjd.15931
 41. Jin F, Vajdic CM, Poynten IM, McGee-Avila JK, Castle PE, Grulich AE. Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis. *Lancet Oncol*. 2024;25(7):933-944. doi:10.1016/S1470-2045(24)00189-X
 42. Garrett GL, Lowenstein SE, Singer JP, He SY, Arron ST. Trends of skin cancer mortality after transplantation in the United States: 1987 to 2013. *J Am Acad Dermatol*. 2016;75(1):106-112. doi:10.1016/j.jaad.2016.02.1155
 43. Shao EX, Betz-Stablein B, Khosrotehrani K, Campbell S, Isbel N, Green AC. Keratinocyte cancer mortality in kidney transplant recipients. *Transplantation*. 2022;106(5):1078-1083. doi:10.1097/TP.0000000000003827
 44. Omland SH, Gnani-deck R, Hædersdal M, Helweg-Larsen J, Omland LH. Skin cancer risk in

- hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study. *JAMA Dermatol*. 2016;152(2):177-183. doi:10.1001/jamadermatol.2015.3902
45. Eggermont CJ, Hollatz A, Wakkee M, et al. Skin cancer risk in more than 200 000 patients with haematological malignancies over 30 years: a nationwide population-based study in the Netherlands. *Br J Dermatol*. 2025;192(6):1029-1037. doi:10.1093/bjd/ljaf027
 46. Omland SH, Ahlström MG, Gerstoft J, et al. Risk of skin cancer in patients with HIV: a Danish nationwide cohort study. *J Am Acad Dermatol*. 2018;79(4):689-695. doi:10.1016/j.jaad.2018.03.024
 47. Ciałczyńska M, Narbutt J, Woźniacka A, Lesiak A. Trends in basal cell carcinoma incidence rates: a 16-year retrospective study of a population in central Poland. *Postepy Dermatol Alergol*. 2018;35(1):47-52. doi:10.5114/ada.2018.73164
 48. Arits AH, Schlangen MH, Nelemans PJ, Kelleners-Smeets NW. Trends in the incidence of basal cell carcinoma by histopathological subtype. *J Eur Acad Dermatol Venereol*. 2011;25(5):565-569. doi:10.1111/j.1468-3083.2010.03839.x
 49. Chambers DB, Ghosh S, Taher MS, Salopek TG. Incidence of nonmelanoma skin cancers in Alberta, Canada, from 2007 to 2018. *J Cutan Med Surg*. 2024;28(3):238-247. doi:10.1177/12034754241232677
 50. Juan HY, Zhou AE, Hoegler KM, Khachemoune A. Overview of familial syndromes with increased skin malignancies. *Arch Dermatol Res*. 2023;315(4):707-727. doi:10.1007/s00403-022-02447-8
 51. Arafa A, Mostafa A, Navarini AA, Dong JY. The association between smoking and risk of skin cancer: a meta-analysis of cohort studies. *Cancer Causes Control*. 2020;31(8):787-794. doi:10.1007/s10552-020-01319-8
 52. Chen ML, Wang SH, Wei JC, Yip HT, Hung YM, Chang R. The impact of human papillomavirus infection on skin cancer: a population-based cohort study. *Oncologist*. 2021;26(3):e473-e483. doi:10.1002/onco.13593
 53. Kuraitis D, Murina A. Squamous cell carcinoma arising in chronic inflammatory dermatoses. *Cutis*. 2024;113(1):29-34. doi:10.12788/cutis.0914
 54. Suárez B, López-Abente G, Martínez C, et al. Occupation and skin cancer: the results of the HELIOS-I multicenter case-control study. *BMC Public Health*. 2007;7:180. doi:10.1186/1471-2458-7-180
 55. Bigler C, Feldman J, Hall E, Padilla RS. Pigmented basal cell carcinoma in Hispanics. *J Am Acad Dermatol*. 1996;34(5 pt 1):751-752. doi:10.1016/S0190-9622(96)90007-9
 56. Kikuchi A, Shimizu H, Nishikawa T. Clinical histopathological characteristics of basal cell carcinoma in Japanese patients. *Arch Dermatol*. 1996;132(3):320-324. doi:10.1001/archderm.1996.03890270096014
 57. van Winden MEC, Hettterschijt CRM, Bronkhorst EM, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK. Evaluation of watchful waiting and tumor behavior in patients with basal cell carcinoma: an observational cohort study of 280 basal cell carcinomas in 89 patients. *JAMA Dermatol*. 2021;157(10):1174-1181. doi:10.1001/jamadermatol.2021.3020
 58. Mills KC, Kwatra SG, Feneran AN, et al. Itch and pain in nonmelanoma skin cancer: pain as an important feature of cutaneous squamous cell carcinoma. *Arch Dermatol*. 2012;148(12):1422-1423. doi:10.1001/archdermatol.2012.3104
 59. Askari SK, Schram SE, Wenner RA, et al. Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population. *J Am Acad Dermatol*. 2007;56(5):739-747. doi:10.1016/j.jaad.2006.11.032
 60. Youl PH, Janda M, Aitken JF, Del Mar CB, Whiteman DC, Baade PD. Body-site distribution of skin cancer, pre-malignant and common benign pigmented lesions excised in general practice. *Br J Dermatol*. 2011;165(1):35-43. doi:10.1111/j.1365-2133.2011.10337.x
 61. Reiter O, Mimouni I, Gdalevich M, et al. The diagnostic accuracy of dermoscopy for basal cell carcinoma: a systematic review and meta-analysis. *J Am Acad Dermatol*. 2019;80(5):1380-1388. doi:10.1016/j.jaad.2018.12.026
 62. Dinnes J, Deeks JJ, Chuchu N, et al; Cochrane Skin Cancer Diagnostic Test Accuracy Group. Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults. *Cochrane Database Syst Rev*. 2018;12(12):CD011901. doi:10.1002/14651858.CD011901.pub2
 63. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Basal Cell Skin Cancer, Version 2.2025. Published 2025. Accessed August 8, 2025. <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1416>
 64. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Squamous Cell Skin Cancer, Version 2.2025. Published 2025. Accessed August 8, 2025. <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1465>
 65. Schmultz CD, Blitzblau R, Aasi SZ, et al. Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2023;21(11):1181-1203. doi:10.6004/jnccn.2023.0056
 66. Amici JM, Rogues AM, Lasheras A, et al. A prospective study of the incidence of complications associated with dermatological surgery. *Br J Dermatol*. 2005;153(5):967-971. doi:10.1111/j.1365-2133.2005.06861.x
 67. Tolkachjov SN, Brodland DG, Coldiron BM, et al. Understanding Mohs micrographic surgery: a review and practical guide for the nondermatologist. *Mayo Clin Proc*. 2017;92(8):1261-1271. doi:10.1016/j.mayocp.2017.04.009
 68. Alam M, Ibrahim O, Nodzenski M, et al. Adverse events associated with Mohs micrographic surgery: multicenter prospective cohort study of 20 821 cases at 23 centers. *JAMA Dermatol*. 2013;149(12):1378-1385. doi:10.1001/jamadermatol.2013.6255
 69. Stewart JR, Lang ME, Brewer JD. Efficacy of nonexcisional treatment modalities for superficially invasive and in situ squamous cell carcinoma: a systematic review and meta-analysis. *J Am Acad Dermatol*. 2022;87(1):131-137. doi:10.1016/j.jaad.2021.07.067
 70. Bastos LMH, Carvalho LP, Haddad GR, Miola AC, Schmitt JV. Curettage and electrocoagulation versus surgical excision in the treatment of low-risk basal cell carcinoma—postoperative follow-up and satisfaction at three months: randomized clinical trial. *An Bras Dermatol*. 2022;97(3):384-386. doi:10.1016/j.abd.2020.12.011
 71. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. *Arch Dermatol*. 2009;145(12):1431-1438. doi:10.1001/archdermatol.2009.291
 72. Shi L, Yang J, Zhang L, et al. Adverse reactions of ALA-PDT for the treatment of cutaneous diseases: a retrospective study. *Photodiagnosis Photodyn Ther*. 2022;38:102783. doi:10.1016/j.pdpdt.2022.102783
 73. Blixt E, Nelsen D, Stratman E. Recurrence rates of aggressive histologic types of basal cell carcinoma after treatment with electrodesiccation and curettage alone. *Dermatol Surg*. 2013;39(5):719-725. doi:10.1111/dsu.12122
 74. Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N. Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. *J Am Acad Dermatol*. 2007;56(1):91-95. doi:10.1016/j.jaad.2006.07.007
 75. Galles E, Parvataneni R, Stuart SE, Linos E, Grewal S, Chren MM. Patient-reported outcomes of electrodesiccation and curettage for treatment of nonmelanoma skin cancer. *J Am Acad Dermatol*. 2014;71(5):1026-1028. doi:10.1016/j.jaad.2014.06.038
 76. O'Neill JL, Lee YS, Solomon JA, et al. Quantifying and characterizing adverse events in dermatologic surgery. *Dermatol Surg*. 2013;39(6):872-878. doi:10.1111/dsu.12165
 77. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. *J Am Acad Dermatol*. 2004;50(5):722-733. doi:10.1016/j.jaad.2003.11.066
 78. Arits AH, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. *Lancet Oncol*. 2013;14(7):647-654. doi:10.1016/S1473-2045(13)70143-8
 79. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. *Br J Dermatol*. 2007;157(suppl 2):41-46. doi:10.1111/j.1365-2133.2007.08272.x
 80. American Society for Radiation Oncology. ASTRO guideline on definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin. Updated February 2020. Accessed May 5, 2025. <https://www.astro.org/provider-resources/guidelines/skin-cancer-guideline>
 81. Boudreaux B, Christensen H, Porter HJ, et al. Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site managed by watchful waiting: a retrospective cohort study. *J Am Acad Dermatol*. 2025;92(4):801-806. doi:10.1016/j.jaad.2024.11.067

82. Logan S, Porter HJ, Lowry J, et al. Oncologic outcomes for squamous cell carcinoma in situ with a clinically resolved biopsy site managed by watchful waiting. *Dermatol Surg*. 2024;50(8):710-713. doi:10.1097/DSS.0000000000004202
83. Henrikson NB, Ivlev I, Blasi PR, et al. Skin cancer screening: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. 2023;329(15):1296-1307. doi:10.1001/jama.2023.3262
84. American Academy of Dermatology. Skin cancer. Updated June 4, 2024. Accessed September 2, 2024. <https://www.aad.org/media/stats-skin-cancer>
85. Jambusaria-Pahlajani A, Crow LD, Lowenstein S, et al. Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study. *Transpl Int*. 2019;32(12):1259-1267. doi:10.1111/tri.13493
86. Gómez-Tomás Á, Bouwes Bavinck JN, Genders R, et al. External validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a large European solid organ transplant recipient cohort. *JAMA Dermatol*. 2023;159(1):29-36. doi:10.1001/jamadermatol.2022.4820
87. Wehner MR, Linos E, Parvataneni R, Stuart SE, Boscardin WJ, Chren MM. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. *JAMA Dermatol*. 2015;151(4):382-388. doi:10.1001/jamadermatol.2014.3307
88. Song F, Qureshi AA, Giovannucci EL, et al. Risk of a second primary cancer after non-melanoma skin cancer in white men and women: a prospective cohort study. *PLoS Med*. 2013;10(4):e1001433. doi:10.1371/journal.pmed.1001433
89. American Academy of Dermatology. How to prevent skin cancer. Published 2024. Accessed September 6, 2024. <https://www.aad.org/public/diseases/skin-cancer/prevent/how>
90. van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. *Cancer Epidemiol Biomarkers Prev*. 2006;15(12):2546-2548. doi:10.1158/1055-9965.EPI-06-0352
91. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. *J Clin Oncol*. 2011;29(3):257-263. doi:10.1200/JCO.2010.28.7078
92. Ulrich C, Jürgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. *Br J Dermatol*. 2009;161(suppl 3):78-84. doi:10.1111/j.1365-2133.2009.09453.x
93. American Academy of Dermatology. Practice safe sun. Published 2025. Accessed March 5, 2025. <https://www.aad.org/public/everyday-care/sun-protection/shade-clothing-sunscreen/practice-safe-sun>
94. Navsaria LJ, Li Y, Nowakowska MK, et al. Incidence and treatment of actinic keratosis in older adults with Medicare coverage. *JAMA Dermatol*. 2022;158(9):1076-1078. doi:10.1001/jamadermatol.2022.2555
95. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. *N Engl J Med*. 2015;373(17):1618-1626. doi:10.1056/NEJMoa1506197
96. Chen AC, Martin AJ, Dalziel RA, et al. A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients. *Br J Dermatol*. 2016;175(5):1073-1075. doi:10.1111/bjd.14662
97. Allen NC, Martin AJ, Snaird VA, et al. Nicotinamide for skin-cancer chemoprevention in transplant recipients. *N Engl J Med*. 2023;388(9):804-812. doi:10.1056/NEJMoa2203086
98. Weinstock MA, Thwin SS, Siegel JA, et al; Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group. Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial. *JAMA Dermatol*. 2018;154(2):167-174. doi:10.1001/jamadermatol.2017.3631
99. Badri O, Schmults CD, Karia PS, Ruiz ES. Efficacy and cost analysis for acitretin for basal and squamous cell carcinoma prophylaxis in renal transplant recipients. *Dermatol Surg*. 2021;47(1):125-126. doi:10.1097/DSS.0000000000002423